Hydroxyprogesterone caproate


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IM Recurrent miscarriage 250-500 mg/wk during the 1st half of pregnancy. Amenorrhoea or abnormal uterine bleeding 375 mg as a single dose; may repeat at 4-wkly intervals if needed. After 4 days of desquamation, or if there is no bleeding w/in 21 days after administration of the drug, may initiate cyclic therapy that includes an oestrogen. Palliation of advanced, inoperable endometrial carcinoma Initial: ≥1 g, may repeat once or more times wkly. Usual: 1-7 g/wk. Discontinue if relapse occurs or if the objective response is not achieved after 12 wk of treatment.
Dosage Details
Intramuscular
Recurrent miscarriage
Adult: 250-500 mg wkly during the 1st half of pregnancy.

Intramuscular
Palliative treatment of advanced, inoperable endometrial carcinoma
Adult: Usual dose: ≥1 g, may repeat once or more times wkly. Usual range: 1-7 g/wk. Discontinue treatment if relapse occurs or if the objective response is not achieved after 12 wk of treatment.

Intramuscular
Abnormal uterine bleeding, Amenorrhoea
Adult: Single dose of 375 mg; may repeat at 4-wkly intervals if needed. After 4 days of desquamation, or if there is no bleeding within 21 days after admin of the drug, may initiate cyclic therapy that includes an oestrogen. For cyclic treatment (28-day cycle): Administer 20 mg of estradiol valerate on day 1, and on day 15, administer 250 mg of hydroxyprogesterone caproate and 5 mg of estradiol valerate. May repeat cyclic therapy at 4-wkly intervals as needed.
Contraindications
Undiagnosed vaginal bleeding, breast cancer, pregnancy, lactation. Thrombophlebitis, thromboembolic disorders, cerebral apoplexy or a history of these conditions. Markedly impaired liver function.
Special Precautions
Physical examination is advised prior to starting therapy. Hepatic impairment, mental depression. Monitor blood glucose in diabetic patients. Discontinue treatment upon signs of thromboembolic and thrombotic disorders. Discontinue treatment if unexplained, sudden or gradual, partial or complete loss of vision, protopsis, diplopia or papilledema, retinal vascular lesions or migraine occur. Caution when used in patients with conditions that might be worsened by fluid retention (e.g. asthma, seizure disorders, migraine, cardiac or renal dysfunction).
Adverse Reactions
GI disturbances, increased appetite, wt gain or loss, oedema, acne, allergic skin rashes, urticaria, mental depression, discomfort in breast; cough, dyspnoea, circulatory disturbances. Pain at site of inj.
IM/Parenteral: B
Drug Interactions
Increased clearance when used with enzyme inducers e.g. carbamazepine and phenytoin. May inhibit metabolism of ciclosporin.
Lab Interference
May cause abnormal thyroid function test results. May alter metyrapone test and LFT.
Action
Description: Hydroxyprogesterone caproate stimulates luteal actions, changes in uterus and vagina as seen in early pregnancy. It also has prolonged uterotrophic effect. Contractile response of the myometrium to oxytocin is inhibited.
Duration: 7-14 days.
Storage
Store at 15-30 °C.
Disclaimer: This information is independently developed by MIMS based on Hydroxyprogesterone caproate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Hiprogin
  • Proluton Depot
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in